Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-Ranging Study of Oral Lasmiditan in Acute Migraine
NCT00883051Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2009
- Primary completion
- Feb 2010
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial of lasmiditan in migraine (5 arms), sponsored by Eli Lilly and Company. Primary endpoint: Percentage of Participants With Headache Response. Started Jul 2009; status: completed.
02
Drugs
lasmiditan
03
Conditions
migraine
Beyond the preview
Go deeper on NCT00883051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00883051.